P.S
From Drugs.com
Cardiovascular
During clinical trials in patients with established cardiovascular disease (CVD) or diabetes plus and additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 hours or more occurred in 3% of patients (n=127) receiving this drug compared with 2% (n=84) placebo-treated patients. The incidence of atrial fibrillation was greater in patients with a history of atrial fibrillation or atrial flutter.
Common (1% to 10%): Atrial fibrillation/flutter, peripheral edema